75994 Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 

graft versus leukemia and other antitumor effects however they can also 

cause potentially lethal graft versus host 

disease (GVHD), requiring posttransplant immunosuppression. Such 

immunosuppression may place patients 

at a greater risk of contracting 

potentially fatal cytomegalovirus 

infection further reducing their capacity 

to be cured of their malignant disease. 

The transfer of T lymphocytes specific 

for leukemia cells or micro-organism 

antigens can be useful since therapeutic 

immune effects would be enhanced 

while GVHD reactions would not be 

induced. Currently available methods 

for isolating and expanding antigenspecific T cells including selection 

using HLA tetramers, magnetic beads 

binding to activation markers or 

laborious limiting dilution techniques 

are unreliable, poorly reproducible, 

expensive and impede clinical progress. 

The present invention relates to 

methods for selecting and expanding 

antigen specific T-cells that recognize a 

pre selected target antigen, to purified 

populations of antigen-specific T cells 

that recognize a pre selected target 

antigen and to therapeutic uses of 

antigen-specific T cells that recognize a 

pre selected target antigen. Potential 

applications include treatment of 

cytomegalovirus, Epstein-Barr virus and 

adenovirus reactivation following stem 

cell transplantation or organ 

transplantation, prevention and 

treatment of leukemic relapse after 

transplantation or chemotherapy using 

autologous expanded T cells, and 

selective depletion of alloreactive T 

cells from transplants which may 

produce GVHD. 

Novel Compounds for Selectively 

Inactivating Pain Pathways 

Peter Blumberg, Jeewoo Lee (NCI). 

U.S. Provisional Application No. 60/

558,003 filed 26 Mar 2004 (DHHS 

Reference No. E–141–2004/0–US–01). 

Licensing Contact: Norbert Pontzer; 301/

435–5502; pontzern@mail.nih.gov.

Available for licensing are 

compositions and methods for the longterm control of pain and other 

pathological conditions caused by the 

over-activity of pain pathways. Neurons 

in the dorsal root, trigeminal and 

nodose ganglia project unmyelinated Cfibers and Ad-fibers that transmit pain 

and temperature sensation between the 

periphery and spinal cord. Along with 

acute and chronic pain, over activation 

of those pathways leads to neurogenic 

and neuropathic inflammation leading 

to such conditions as post-herpetic 

neuralgia, diabetic neuropathy, cystitis, 

and reflex sympathetic dystrophy 

among many others. 

These neurons are activated both 

centrally and peripherally by a 

relatively non-selective cation channel 

initially identified as site of action of 

capsaicin, the pungent ingredient in 

chili peppers. That channel is now 

called VR1 or TRPV1 and is found in 

high concentration only on C and Ad

neurons. These inventors previously 

discovered and patented resiniferatoxin 

(RTX), an ultrapotent agonist of the VR1 

receptor. RTX desensitizes C and Adfibers when applied peripherally and 

may selectively ablate those neurons 

when applied centrally without causing 

substantial pain from activation of the 

neurons. RTX type compounds thus 

provide a method of controlling pain 

other conditions caused by C and Adfiber activity. The present invention 

provides new RTX analogues that may 

have an improved therapeutic index and 

metabolic profile.

Dated: December 9, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–27783 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel. 

Date: December 16–17, 2004. 

Time: December 16, 2004, 7 p.m. to 10 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Stanford University, Stanford 

Terrace Inn, 531 Stanford Avenue, Palo Alto, 

CA 94306. 

Time: December 17, 2004, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Stanford University, Stanford 

Terrace Inn, 531 Stanford Avenue, Palo Alto, 

CA 94306. 

Contact Person: Ken D. Nakamura, PHD, 

Scientific Review Administrator, Office of 

Scientific Review, National Human Genome 

Research Institute, National Institutes of 

Health, Bethesda, MD 20892, (301) 402–0838. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domstic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: December 14, 2004. 

Anna P. Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27779 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Council on Drug 

Abuse. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: February 15–16, 2005. 

Closed: February 15, 2005, 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Open: February 16, 2005, 9 a.m. to 4 p.m.